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growth factors therein contained. Similarly, we are confident that if
the experiments were repeated using higher platelet doses, their
findings would completely different. Finally, we wonder about the
exceedingly broad spectrum of exclusion criteria. Many of our
patients are elderly, are diabetic, may have coexisting diseases
including rheumatic diseases, may have exposed bone or tendon,
or may have very limited mobility. Actually, it is these kinds of
patients who can particularly benefit of treatment with platelet-
derived growth factors.
Piero Borzini, MD
Laura Mazzucco, DSc
Renzo Panizza, MD
Giorgio Rivara, MD
Blood Transfusion Service & Plastic and Reconstructive Surgery
Ospedale SS Antonio e Biagio
Alessandria, Italy
REFERENCES
1. Carter CA, Jolly DG, Worden CE Sr, Hendren DG, Kane CJM. Platelet-
rich plasma gel promotes differentiation and regeneration during equine
wound healing. Exp Molec Pathol 2003;74:244-55.
2. Gruber R, Karreth F, Fromlet F, Fischer MB, Watzek G. Platelets are
mitogenic for Periostium-derived cells. J Orthop Res 2003;5:941-8.
doi:10.1016/j.jvs.2004.01.047
Reply
We thank Dr Piero Borzini and colleagues for their interest in
our article, and we want to answer to their remarks. Borzini et al
discuss three points: (1) the platelet concentration of the product
tested for its wound healing adjuvant effect and the quantity of
platelets applied on the wound to treat, (2) the platelet product
used for cutaneous wound healing, and (3) the choice of chronic
cutaneous lesions to treat with a platelet adjuvant therapy. Con-
cerning the first point, we applied a lower quantity of platelets than
Borzini et al (10 vs 0.2-0.4 10 platelets/cm) from a preparation
at 5  10 platelets/mL (vs 1-2  10/mL). We observed in vitro
biological effects induced by platelet lysates, with a maximal effect
observed at 10 platelets/mL on normal dermal fibroblasts at an
early passage, grown in monolayer as well as in a tridimensionnal
matrix. The observed effects concerned cell growth as well as
stimulation by platelets of fibroblast cytokine production. The
Figure presents the fibroblast growth curves in the presence of
three different platelet concentrations, 10 platelets /mL corre-
sponding to 10% platelets in the letter of Borzini et al. The cell
growth was tested by an MTT test as previously reported by others
and by us.1 We point out that a significant proliferative effect is
already observed at day 3 with 5  10 platelets/mL.
Concerning the second point, the platelet preparation is in-
deed a crucial point, as is discussed in our article. Borzini et al used
a platelet gel obtained by thrombin activation of platelet-rich
plasma. This kind of preparation contains platelet growth factors
and adhesive proteins but also lipid mediators and a fibrin matrix
that mimics the matrix of the first steps of cutaneous wound
healing.2
Then, we arrive at the third point. Evaluation of the healing
effect is the key point in clinical trials on wound healing. Many
patients may improve with an adjuvant local treatment as a dress-
ing, only because they are included in a trial, with good local
wound care and adequate compression therapy. Thus, concerning
venous ulcers, it is absolutely necessary to test therapeutic hypoth-
eses in trials with a control group, and to take the rate and time to
complete healing at end points of the study. Therefore, to obtain
homogeneous comparable groups of patients, we excluded pa-
tients who presented with wounds that were not only from venous
origin, such as patients with an uncontrolled systemic disease, as
well as patients with bad local conditions such as bone exposition.
It is important to emphasize that Stacey at al3 observed no platelet
adjuvant effect for the closure of venous leg ulcers, using sonni-
cated platelets in phosphate buffer saline at 3  10/cm. As
discussed in our article, diabetic foot ulcers, but not venous leg
ulcers, appear today to be good candidates for an adjuvant treat-
ment with platelet products or recombinant growth factors. To our
knowledge, no clinical trial has tested the therapeutic adjuvant
effect of activated platelets in a fibrin gel for the closure of chronic
cutaneous lesions.
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